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Background: Medulloblastoma (MB) is the most common type of malignant childhood brain tumour. Although
deregulated microRNA (miRNA) expression has been linked to MB pathogenesis, the selection of appropriate
candidate endogenous control (EC) reference genes for MB miRNA expression profiling studies has not been
systematically addressed. In this study we utilised reverse transcriptase quantitative PCR (RT-qPCR) to identify the
most appropriate EC reference genes for the accurate normalisation of miRNA expression data in primary human
MB specimens and neural stem cells.
Results: Expression profiling of 662 miRNAs and six small nuclear/ nucleolar RNAs in primary human MB specimens,
two CD133+ neural stem cell (NSC) populations and two CD133- neural progenitor cell (NPC) populations was
performed using TaqMan low-density array (TLDA) cards. Minimal intra-card variability for candidate EC reference
gene replicates was observed, however significant inter-card variability was identified between replicates present on
both TLDA cards A and B. A panel of 18 potentially suitable EC reference genes was identified for the normalisation
of miRNA expression on TLDA cards. These candidates were not significantly differentially expressed between
CD133+ NSCs/ CD133- NPCs and primary MB specimens. Of the six sn/snoRNA EC reference genes recommended
by the manufacturer, only RNU44 was uniformly expressed between primary MB specimens and CD133+ NSC/
CD133- NPC populations (P= 0.709; FC = 1.02). The suitability of candidate EC reference genes was assessed using
geNorm and NormFinder software, with hsa-miR-301a and hsa-miR-339-5p found to be the most uniformly
expressed EC reference genes on TLDA card A and hsa-miR-425* and RNU24 for TLDA card B.
Conclusions: A panel of 18 potential EC reference genes that were not significantly differentially expressed
between CD133+ NSCs/ CD133- NPCs and primary human MB specimens was identified. The top ranked EC
reference genes described here should be validated in a larger cohort of specimens to verify their utility as controls
for the normalisation of RT-qPCR data generated in MB miRNA expression studies. Importantly, inter-card variability
observed between replicates of certain candidate EC reference genes has major implications for the accurate
normalisation of miRNA expression data obtained using the miRNA TLDA platform.
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Medulloblastoma (MB) is the most common malignant
paediatric brain tumour, and a major cause of childhood
cancer related morbidity and mortality [1]. Several mo-
lecular subtypes of MB have been identified on the basis
of specific gene expression signatures [2-6], suggesting
that different sub-groups may arise from distinct cells of
origin. In human MB, a subpopulation of CD133-
expressing cells was identified that displayed similar
properties to NSCs, including self-renewal and multipo-
tency [7,8]. Additional studies demonstrated that these
putative brain tumour stem cells (BTSCs) were capable
of initiating tumour formation in immunodeficient mice
[9]. These human data combined with evidence from
two different murine MB models [10,11] strongly impli-
cate CD133+ NSCs as a cell of origin for a subset of
MB.
MicroRNAs (miRNAs) are a class of short, non-coding
RNAs that down-regulate gene expression at a post-
transcriptional level [12,13]. Functioning as guide mole-
cules for silencing complexes, miRNAs utilise anti-sense
complementarity to inhibit the expression of specific
messenger RNA (mRNA) targets by either repressing
translation and/or inducing deadenylation and subse-
quent mRNA degradation [13-16]. miRNAs play key
regulatory roles in various cellular processes including
cell proliferation [17], apoptosis [18] and differentiation
[19]. Numerous studies have demonstrated significantly
altered miRNA expression patterns in a wide range of
human cancer types compared to normal tissues, sug-
gesting that specific miRNAs might act as tumour sup-
pressor genes or oncogenes (Reviewed in [20] and [21]).
In addition to their potential as novel molecules for can-
cer therapy [22], miRNAs represent an emerging class of
diagnostic and prognostic markers [23-26].
Adaptations of existing technologies for gene expression
profiling including RT-qPCR, chip-based microarrays, and
next generation sequencing have enabled the high-
throughput profiling of miRNA expression [23,27-31].
The accuracy of these methods is dependent upon cor-
recting for non-biological sample-to-sample variation that
could be introduced during the steps from sample prepar-
ation to amplification [23]. For miRNA RT-qPCR expres-
sion data, several methods have been described to correct
for this variation, the most frequent of which is the nor-
malisation to endogenous control (EC) reference genes
[32]. An ideal reference gene should be highly expressed,
exhibit minimal expression level variation in cells or tis-
sues under investigation, and be of similar length to that
of the target gene [33]. Additionally, extraction and quan-
tification efficiency and storage stability of an ideal refer-
ence gene should be equivalent to the gene under
investigation [33]. However, previous studies have demon-
strated that a single universal EC reference gene withthese properties for all cell or tissue types is unlikely to
exist [34-37]. Normalisation of RT-qPCR data to unreli-
able reference genes may lead to incorrect quantification
of miRNAs of interest [33,38], and the importance of val-
idating suitable candidate EC reference genes in a cell
and/or tissue-specific context has been demonstrated pre-
viously [33]. Although several research groups have per-
formed miRNA expression profiling studies in primary
MB specimens, the validation strategies for the selection
of EC genes for normalisation of miRNA gene expression
data were not reported [39-45]. Additionally, none of
these studies profiled CD133+ NSCs and/or CD133-
NPCs, instead normalising miRNA expression to EC gene
expression levels in human adult and fetal cerebellum.
This study describes a robust strategy for the identification
of suitable EC genes for the normalisation of miRNA RT-
qPCR data in MB profiling studies. Using the main selec-
tion criteria of good measurability and uniform expres-
sion, candidate EC reference genes for miRNA data
normalisation were investigated in nine primary MB spe-
cimens, and two populations of CD133+ NSCs and
CD133- NPCs. The uniformity of expression of these
candidate EC genes was subsequently investigated across
all samples, with the relative quantities of miRNAs,
hsa-miR-144*, hsa-miR-21* and hsa-miR-923 assessed
using five different normalisers, to determine the impact
of EC reference gene selection on relative expression
of individual miRNAs of interest.
Results
Inter-card variation for candidate small nuclear (sn) and
small nucleolar (snoRNA) EC reference genes on the TLDA
platform
miRNA profiling using the TLDA system consists of two
cards, A and B. Card A contains three proposed EC
references genes, MammU6, RNU44 and RNU48, and
card B contains six, MammU6, RNU44, RNU48, RNU24,
RNU43 and RNU6B. To evaluate whether there was
inter-plate variation between the sn/snoRNA candidate
EC reference genes on TLDA card A and card B, Cq
values for technical replicates of three candidate EC
reference genes, MammU6, RNU48 and RNU44, present
on separate TLDA cards were plotted and one way ana-
lysis of variance (ANOVA) was applied to assess inter-
plate variation between the technical replicates (Figure 1).
Significant variation was observed between the technical
replicates of MammU6 (P= 0.025) and RNU44
(P= 0.0030) on TLDA cards A and B (Figure 2). In con-
trast, Cq values for the technical replicates of RNU48
remained relatively stable (P= 0.97). The observed differ-
ences between EC reference gene replicate Cq values on
TLDA cards A and B suggests that the normalisation of
miRNAs is best performed to EC reference genes on the
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Figure 1 Quantification cycle (Cq) values for the technical replicates of proposed EC reference genes of the (TLDA) cards A (left) and B
(right).
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cards A and B. As minimal variation was observed for
technical replicates of candidate EC reference genes on
the same TLDA card, an average of the technical repli-
cates from each TLDA card was employed for further
analysis. Because this approach limited the maximum
number of proposed sn/snoRNA candidate EC reference
genes for each TLDA card, particularly for TLDA card
A, we expanded the panel of potential candidate EC
reference genes under investigation to include miRNAs
that fulfil the appropriate selection criteria outlined in
methods.
Expression of candidate EC reference genes in primary
MB specimens, CD133+ NSCs and CD133- NPCs
Suitable candidate EC reference genes must display con-
sistent expression between normal and treatment and/or
disease groups. Two sample t-tests were employed to as-
sess whether candidate EC reference genes were differen-
tially expressed between primary MB specimens andCD133+ NSC/ CD133- NPC populations. For TLDA card
A, 12 genes were identified as potentially suitable EC
reference genes (Table 1). Of the proposed sn/snoRNA
candidate EC reference genes, only RNU44 was uniformly
expressed across primary MB specimens and CD133+
NSC/CD133- NPC populations (P=0.71; fold change
(FC) = 1.02) (Table 1). In contrast, MammU6 was over-
expressed in primary MB specimens compared to NSC/
NPCs (P=0.049; FC=3.66), and while the over-expression
of RNU48 did not reach statistical significance (P=0.35),
the degree of over-expression observed in primary MB
specimens relative to NSCs/NPCs (FC=2.35) suggested
RNU48 was not an ideal EC reference in this context. In
addition to RNU44, a number of candidate miRNAs were
uniformly expressed in NSCs and NPCs and primary MB
specimens (P≥ 0.05; FC≤±1.5), highlighting their poten-
tial as EC reference genes in this study.
Expression analysis identified six candidate EC refer-
ence genes of TLDA card B suitable for data normalisa-
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Figure 2 Quantification cycle (Cq) values for technical replicates of (A) MammU6 (B) RNU44 and (C) RNU48 across all samples for
TaqMan low density array (TLDA) cards A and B.
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no significant difference was observed for RNU44
(P= 0.97; FC= 1.49) and RNU24 (P= 0.42; FC= 1.19) be-
tween primary MB samples and NSCs/NPCs. Similar to
findings obtained for TLDA card A, increased expres-
sion of RNU48 in primary MB specimens (FC = 2.64), al-
though not statistically significant (P= 0.25), suggests it
may not be the most appropriate EC reference for nor-
malisation. Significantly increased expression of
MammU6, RNU6B and RNU43 was identified inprimary MB specimens relative to CD133+ NSCs/
CD133- NPCs, particularly for RNU43 (~ 500 fold
greater expression in primary MB). In addition to the
two snoRNAs, RNU44 and RNU24, four miRNAs were
also uniformly expressed in the two groups, namely
miR-425* (P= 0.49; FC = 1.42), miR-877 (P= 0.35; FC=
1.39), miR-130b* (P= 0.91, FC=−1.13) and miR-181a-2*
(P= 0.97; FC = 1.48).
To compare the abundance of candidate EC reference
genes selected for further analysis and to obtain an
Table 1 Summary of candidate EC reference genes identified for the normalisation of miRNA expression data in MB
Gene Chromosomal location p value Fold change Coefficient of variation Candidate EC gene
Card A
RNU48 6p21.33 0.351 2.36 9.52 No
RNU44 1q25.1 0.709 1.02 6.50 Yes
MammU6 15q23 0.049 3.66 11.10 No
hsa-miR-133a 18q11.2/ 20q13.33 0.797 1.16 7.05 Yes
hsa-miR-339-5p 7p22.3 0.218 1.47 5.89 Yes
hsa-miR-214 1q24.3 0.853 1.36 8.45 Yes
hsa-miR-197 1p13.3 0.515 -1.41 5.65 Yes
hsa-miR-18a 13q31.3 0.687 1.09 9.64 Yes
hsa-miR-210 11p15.5 0.766 1.41 6.07 Yes
hsa-miR-328 16q22.1 0.564 1.46 7.40 Yes
hsa-miR-301a 17q22 0.384 1.32 7.23 Yes
hsa-miR-218 4p15.31 0.592 1.14 9.86 Yes
hsa-miR-149 2q37.3 0.647 -1.36 7.97 Yes
hsa-miR-20b Xq26.2 0.397 -1.03 9.32 Yes
Card B
RNU48 6p21.33 0.250 2.64 9.50 No
RNU44 1q25.1 0.968 1.49 6.61 Yes
MammU6 15q23 0.023 4.29 13.25 No
RNU24 9q34 0.423 1.19 4.77 Yes
RNU43 22q13 <0.01 498.00 21.50 No
RNU6B 10p13 <0.01 14.98 9.16 No
hsa-miR-425* 3q21.31 0.493 1.42 4.53 Yes
hsa-miR-877 6p21.33 0.350 1.39 3.33 Yes
hsa-miR-130b* 22q11.2 0.910 -1.13 6.39 Yes
hsa-miR-181a-2* 9q33.3 0.972 1.48 6.10 Yes
Uniformly and differentially expressed snoRNA candidate EC reference genes from both TLDA cards A and B are listed with chromosomal location.
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+ NSC/ CD133-NPCs and primary MB specimens, Cq
values of each candidate EC reference gene were plotted
and the coefficient of variation (CV) for each candidate
EC reference gene calculated (Figure 3). The mean, CV
and range of Cq values for all candidate EC reference
genes are shown in Table 2. For TLDA card A, miR-20b
had the highest expression with a mean Cq of 17.75, fol-
lowed by miR-149 and miR-218 both with a mean Cq
value of 18.88. Moderately abundant EC reference genes
with mean Cq values between 20 and 25, included miR-
18a, miR-133a, miR-197, miR-210, miR-214, miR-328
and RNU44. All candidates displayed low variability,
with the least variation across all samples for miR-197
(CV= 5.65), and the largest for miR-218 (CV=9.86).
Candidate EC reference genes from TLDA card B were
expressed at lower levels, with RNU44 the most highly
expressed gene with a mean Cq value of 20.98. Closely
following RNU44 were miR-181a-2* and RNU24, withmean Cq values of 21.22 and 21.53, respectively. miR-
425* was the lowest expressed EC reference gene, with a
mean Cq value of 24.87. Candidates again displayed low
variability, with miR-877 exhibiting the smallest Cq vari-
ation (CV= 3.33), and RNU44 (CV= 6.60) the largest.
Uniformity of candidate reference gene expression in
primary MB specimens, CD133+ NSCs and CD133- NPCs
Candidate EC reference genes displaying similar expres-
sion levels in CD133+ NSC/ CD133- NPCs and primary
MB specimens were further assessed for uniformity of ex-
pression across all samples using geNorm [36] and Norm-
Finder [46] software. RNU48 was also included in this
analysis, as although differential expression of this
snoRNA, as measured by FC, was observed between pri-
mary MB specimens and CD133+ NSCs/ CD133- NPCs,
this did not reach statistical significance. The chromo-
somal location of candidate EC reference genes was























































































Figure 3 Variation in expression of all candidate EC reference genes of (TLDA) card A and B identified as uniformly expressed between
primary medulloblastoma (MB) specimens and CD133+ NSCs/ CD133- NPCs. Quantification cycle (Cq) values for candidate EC reference
genes were plotted for each sample. Cq values were also plotted for RNU48, as although differentially expressed, it did not reach statistical
significance.
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(Table 1), as this would lead to an erroneous choice of an
optimum EC gene reference pair using geNorm and
NormFinder software. The ranking of the candidate EC
reference genes determined by these programs is sum-
marised in Table 3, and consistent results were obtained
for both TLDA card A and card B. Normfinder and geN-
orm identified hsa-miR-301a and hsa-miR-339-5p as the
two most uniformly expressed EC reference genes on
TLDA card A, closely followed by hsa-miR-210 and
RNU48. Normfinder identified the geometric mean of
hsa-miR-339-5p and hsa-miR-301a as the most stable pair
of EC reference genes, with a lower combined stability
value of M=0.116 when compared to the stability values
of the EC reference genes alone (Table 3). This suggests
that the combination of hsa-miR-339-5p and hsa-miR-301a should be used for data normalisation in preference
to the single EC reference genes.
Of the candidate EC reference genes on TLDA card B,
hsa-miR-425* and RNU24 were the two most uniform-
ly expressed EC reference genes, followed by RNU48
and hsa-miR-877 (Table 3). The combination of
hsa-miR-425* and RNU24 displayed a much lower
stability value (M= 0.078) than either of the candidate
EC reference genes alone, indicating that the geometric
mean of these EC reference genes is the most suitable
for miRNA expression normalisation of TLDA card B.
Although both programs listed RNU48 in the top four
most uniformly expressed candidate EC reference genes
of TLDA card A and card B, it was not considered ideal
due to its differential expression between primary MB
specimens and CD133+ NSCs/CD133- NPCs.
Table 2 Summary statistics of Cq values for candidate EC
reference genes
Gene Mean Minimum Maximum CV
Card A
RNU48 14.99 12.41 17.49 9.52
RNU44 22.85 20.96 26.43 6.50
hsa-miR-133a 24.97 21.74 28.02 7.05
hsa-miR-339-5p 24.28 21.52 27.43 5.89
hsa-miR-214 22.29 18.88 25.05 8.45
hsa-miR-197 21.94 19.20 22.97 5.65
hsa-miR-18a 21.54 17.25 24.64 9.64
hsa-miR-210 20.96 19.25 23.06 6.07
hsa-miR-328 20.50 17.61 22.98 7.40
hsa-miR-301a 19.56 16.64 22.58 7.23
hsa-miR-218 18.88 15.21 21.68 9.86
hsa-miR-149 18.88 16.39 20.77 7.97
hsa-miR-20b 17.75 14.36 20.81 9.32
Card B
RNU48 15.30 12.45 17.58 9.50
RNU44 20.98 19.18 24.36 6.60
RNU24 21.53 19.40 23.64 4.77
hsa-miR-425* 24.87 22.83 26.99 4.53
hsa-miR-877 23.99 22.30 25.20 3.33
hsa-miR-130b* 22.39 20.26 24.99 6.39
hsa-miR-181a-2* 21.22 19.47 24.06 6.10
Table 3 Candidate EC reference genes ranked according
to their expression stability as calculated by the geNorm
and NormFinder algorithms
Rank Normfinder geNorm
Gene Stability Gene Stability (M)
Card A
1 hsa-miR-339-5p 0.16 hsa-miR-301a 1.589
2 hsa-miR-301a 0.16 hsa-miR-339-5p 1.603
3 RNU48 0.2 hsa-miR-210 1.634
4 hsa-miR-210 0.22 RNU48 1.680
5 hsa-miR-328 0.26 hsa-miR-197 1.726
6 hsa-miR-20b 0.28 hsa-miR-328 1.785
7 hsa-miR-197 0.3 hsa-miR-149 1.794
8 hsa-miR-133a 0.3 hsa-miR-20b 1.841
9 hsa-miR-149 0.31 hsa-miR-133a 1.954
10 hsa-miR-218 0.32 RNU44 2.074
11 hsa-miR-18a 0.390 hsa-miR-18a 2.169
12 RNU44 0.49 hsa-miR-218 2.188
13 hsa-miR-214 0.59 hsa-miR-214 2.505
Card B
1 hsa-miR-425* 0.11 hsa-miR-425* 1.177
2 RNU24 0.11 RNU24 1.180
3 RNU48 0.16 RNU48 1.299
4 hsa-miR-877 0.23 hsa-miR-877 1.301
5 hsa-miR-130b 0.32 hsa-miR-130b 1.538
6 hsa-miR-181a-2* 0.34 RNU44 1.569
7 RNU44 0.39 hsa-miR-181a-2* 1.860
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quantification of individual miRNAs
To demonstrate the impact of selected EC reference
genes on the results, we measured the expression of miR-
NAs relative to several candidate EC reference genes
identified in this investigation. Specific candidate
snoRNA EC reference genes on TLDA card B were
highly differentially expressed in primary MB specimens
relative to CD133+ NSCs and CD133- NPCs, and there-
fore, as proof of concept, the normalisation of individual
miRNAs focused upon TLDA card B miRNAs and candi-
date EC reference genes. In primary MB specimens, the
over-expression of three TLDA card B miRNAs, hsa-
miR-144*, hsa-miR-21* and hsa-miR-923, was previously
described [47]. For this analysis, normalisation of these
three miRNAs was performed using top ranked candi-
date EC reference genes identified by geNorm and
Normfinder, including hsa-miR-425*, RNU24, hsa-miR-
877, and the EC reference pair, RNU24/ hsa-miR-425*. In
addition, target miRNA expression was also established
relative to the significantly over-expressed (~500 fold)
candidate EC reference gene, RNU43. Normalisation
using uniformly expressed candidate EC reference genes
did not influence the directionality of differentialexpression of miRNAs, with consistent over-expression
of each target miRNA observed in primary MB speci-
mens relative to CD133 +NSCs/CD133- NPCs (Figure 4).
In contrast, down-regulation of all three miRNAs was
observed when RNU43 was utilised for data normalisa-
tion, due to the significant over-expression of RNU43 in
primary MB specimens relative to target miRNA expres-
sion. Taken together, these results emphasise that estab-
lishing target miRNA expression levels for a particular
tissue and/or disease state is strongly influenced by
the candidate EC reference gene chosen for data
normalisation.
Discussion
The importance of validating suitable candidate EC
reference genes in a cell and/or tissue-specific context is
well documented, and a single universal reference gene
for all tissue types is unlikely to exist [33-37]. Indeed, in
the context of cancer, a disease in which the cell of ori-
gin is unknown or inadequately characterised in many
cases, the selection of appropriate EC reference genes is
particularly difficult. Although the cells of origin of the
Figure 4 Quantitative differences in miRNA expression in
medulloblastoma (MB) normalising to different EC reference
genes. The mean fold changes of hsa-miR-923, hsa-miR-144* and
hsa-miR-21* expression in nine primary MB specimens in
comparison to the mean expression of these miRNAs in CD133+
NSCs and CD133- NPCs. Relative expression was determined using
the 2-ΔCq method and log2 transformed. Normalisation was carried
out either to hsa-miR-425* (dark blue), RNU43 (red), hsa-miR-877
(green), RNU24 (purple) or geometric mean of hsa-miR-425* and
RNU24 (light blue). The fold changes of all three miRNAs normalised
against RNU43 was different from the fold changes obtained
following the normalisation against hsa-miR-425*, hsa-miR-877,
RNU24 and the geometric mean of hsa-miR-425* and RNU24.
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been conclusively identified, the available murine data
suggest that SHH-dependent MB may have multiple
cells of origin including cerebellar granule precursor
cells, NSCs [48,49], and cochlear nuclei of the lower
rhombic lip [50]. Other mouse models suggest that
Group 3 MB arise from CD133+ NSCs [11], and WNT-
driven tumours originate from progenitor cells of the
dorsal brainstem [51]. The cell of origin of Group 4
tumors has not yet been determined. On this basis, the
normalisation of gene expression levels in primary MB
specimens to levels in whole foetal or adult cerebellum,
which represent heterogeneous tissues at different devel-
opmental stages, although generally accepted, is likely
to be sub-optimal. Similarly, the normalisation of gene
expression levels in primary human MB to those in
ESC-derived NSCs as described here, may be more
appropriate for the analysis of specific MB subtypes (e.g.,
SHH or Group 3 MB), or stem cell regulatory pathways
in MB pathogenesis. The assessment of miRNA expres-
sion levels in a larger cohort of primary MB specimens
relative to NSCs, and an improved understanding of MB
cells of origin will be necessary to address these issues.
In the meantime, the data reported here represent an
important complementary resource for future MB
miRNA profiling studies.Normalisation based on predefined invariant EC genes
such as sn/snoRNAs is a commonly utilised approach in
miRNA RT-qPCR profiling analysis [52]. However, in the
context of this study, the majority of pre-defined small
nuclear and small nucleolar RNAs were not suitable as
EC reference genes for miRNA data normalisation. Small
non-coding RNAs other than miRNAs do not mirror the
physiochemical properties of miRNA molecules, suggest-
ing that normalisation of miRNA expression data should
be performed with reference genes belonging to the same
RNA class [33,36]. The selection of invariant miRNAs
identified by algorithms specifically tailored to reference
gene ranking by stepwise elimination of the least stable
gene such as geNorm [36], or through statistical linear
mixed-effects modelling such as Normfinder [46] have
been previously identified as superior to sn/snoRNA-
based normalisation [33,53]. Indeed, we identified vari-
ous miRNAs that were more uniformly expressed across
all samples and therefore represent more suitable EC
reference genes than the sn/snoRNAs proposed by the
manufacturer, a finding that was consistent with a num-
ber of previous studies [38,54-57]. Thus, our data provide
further evidence to suggest that miRNAs, in comparison
to other classes of small non-coding RNAs, may be more
suitable EC reference genes for the normalisation of
miRNA expression data, providing their expression
meets the general consensus of moderate abundance and
consistency across all samples.
The overall uniformity of expression is a major deter-
minant for an ideal EC reference gene [33]. Our initial
statistical analyses identified a number of candidate EC
reference genes uniformly expressed across experimental
groups, with both NormFinder and geNorm identifying
hsa-miR-339-5p and hsa-miR-301a as the most stable
EC reference genes for TLDA card A, and hsa-miR-425*
and RNU24 as the most stable for TLDA card B. The
practical consequences of miRNA normalisation were
then evaluated using TLDA card B candidate EC refer-
ence genes and miRNAs as a case study. As evident
from our results, inappropriate use of EC reference
genes can significantly impact upon target miRNA quan-
titation. With the use of suitable EC reference genes, in-
cluding hsa-miR-425*, RNU24, hsa-miR-877 and EC
reference pair, RNU24/hsa-miR-425*, over-expression of
all three miRNAs (hsa-miR-21*, hsa-miR-144* and hsa-
miR-923) was identified, as previously reported [47].
However, when an inappropriate EC reference gene,
RNU43, was used for expression data normalisation, the
down-regulation of all three miRNAs was observed. Sev-
eral previously published studies in a range of other
tissue types have reported similar misleading results
when inappropriate EC reference genes were used
[33,38,54,55,58], highlighting the importance of selecting
appropriate and validated EC reference genes for miRNA
Table 4 Clinical data and molecular sub-type of primary
MB specimens utilised in this investigation
Sample Gender Age M Status Sub-type
M2 Female 3 Unknown B
M6 Male 7 M+ C
M7 Male 1.5 M0 B
M9 Male 2 Unknown N/A
M11 Male 5 M+ DE
M14 Female 3 M0 C
M15 Male 3 M+ DE
M17 Male 4 M+ DE
M22 Male 1 Unknown N/A
Metastatic status was defined as M0 (no metastasis) or M+ (distant
metastases). Primary specimens defined as “N/A” were not available for
sub-typing analysis [47]. Sub-type designations were based on the data of
Kool et al., [3].
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ous MB miRNA profiling studies utilised RNU6B and
RNU66 as an EC reference gene pair for normalisation,
the validation of these reference genes was not reported
[39,41,45]. It is important to note that these previous
studies normalised miRNA expression to EC reference
levels in human normal adult and foetal cerebellum, ra-
ther than CD133+ NSCs/CD133- NPCs profiled in this
investigation. The findings obtained in this study indi-
cated that RNU6B was significantly differentially
expressed in primary MB specimens relative to CD133+
NSCs/CD133- NPCs, and therefore was not a suitable
EC reference gene for normalisation. Unfortunately, the
suitability of RNU66 could not be assessed in this inves-
tigation, as the RNU66 miRNA assay was not included
in the V2.0 TLDA cards. An additional MB miRNA pro-
filing study utilised RNU48 as a single reference gene for
normalisation of miRNA expression data [44]. Differen-
tial expression of RNU48 was observed in this study,
however this did not reach statistical significance and
again, a direct comparison was not possible due to the
different normal control tissues being profiled. Com-
bined, these findings reiterate the importance of validat-
ing suitable candidate EC reference genes in the relevant
cell and/or tissue under investigation.
The performance of miRNA profiling by the high-
throughput TLDA miRNA expression profiling system
has been evaluated in several studies, with high reprodu-
cibility observed for technical replicates of miRNA
assays located on the same TLDA card [53,59-61]. While
we also observed minimal intra-card variability for all
candidate EC reference genes, significant inter-card vari-
ability was apparent between replicates of MammU6 and
RNU44 on TLDA cards A and B. Similar findings were
obtained in a previous study, where differential expres-
sion of MammU6 and RNU44, but not RNU48, was
observed between the same samples profiled on TLDA
cards A and B [61]. For the TLDA system, two separate
Megaplex primer pools are required for reverse tran-
scription (RT) of RNA and pre-amplification of cDNA
prior to application to cards A and B. We propose that
the inter-card variability for replicates of MammU6 and
RNU44 was perhaps a direct consequence of differential
RT and pre-amplification efficiencies of these sn/snoR-
NAs associated with the separate reactions. Previously,
the variable expression of a subset of miRNAs was
largely attributed to the altered efficiencies of the Mega-
plex RT and pre-amplification reactions [53]. Whilst a
systematic evaluation of the inter-card reproducibility of
the miRNA TLDA platform has not been reported, the
findings obtained in this study have important implica-
tions for the normalisation of miRNA expression data
obtained using this system. Future studies should care-
fully assess the potential for inter-card/plate variabilityof the associated platform prior to the assessment of
candidate EC reference genes for data normalisation.Conclusion
A panel of 18 potential EC reference genes that were not
significantly differentially expressed between CD133+
NSCs/ CD133- NPCs and primary human MB speci-
mens was identified. Based on our findings, EC reference
gene pairs hsa-miR-301a and hsa-miR-339-5p and
hsa-miR-425* and RNU24 are recommended for the nor-
malisation of miRNAs on TLDA card A and card B,
respectively, in primary MB specimens relative to
ESC-derived NSCs/ NPCs. The top ranked EC reference
genes described here should be validated in a larger cohort
of specimens to verify their utility as controls for the
normalisation of RT-qPCR data generated in MB miRNA
expression studies. More broadly, inter-card variability
observed between replicates of certain candidate EC
reference genes has major implications for the accurate
normalisation of miRNA expression data obtained using
the miRNATLDA platform.Methods
Patient samples
Nine MB samples were collected from children treated
at Princess Margaret Hospital (PMH) in Perth, Western
Australia. Tumour tissue was embedded in optimal cut-
ting temperature compound (OCT) and snap-frozen.
The age of patients, gender distribution and molecular
sub-type of each primary MB specimen have been previ-
ously described (Table 4) [47]. Written approval to
undertake this study was obtained from the PMH
human ethics committee. Written consent to use
tumour material for research purposes was obtained
from the parents of patients according to PMH ethics
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Neurosphere maintenance and flow cytometry
Human NSCs propagated as neurospheres were derived
from human embryonic stem cell (ESC) lines hES3
(WiCell Research Institute, Madison, WI, USA) and
MEL1 (StemCore, Melbourne, Australia) using protocols
described previously [62,63]. Dissociation of neuro-
spheres and isolation of CD133+ NSCs by flow cytome-
try was performed as described previously [64].
Enrichment of CD133- NPCs was 100% for both hES3
and MEL1 ESC lines, with the enrichment of CD133+
NSCs being 81.1% and 97% for the hES3 and MEL1 ESC
lines, respectively.
Small RNA isolation and enrichment
RNA enriched for small RNAs was isolated from pri-
mary specimens, cell lines and NSC/NPCs using the
miRNeasy mini kit (Qiagen, Melbourne Australia), as
described previously [47]. RNA quantity and purity was
estimated by the ratio of absorbance at 260 nm to that
at 280 nm (OD260:OD280), with ratios of between 1.8
and 2.0 being considered optimal.
miRNA expression profiling
miRNA profiling was performed using quantitative real-
time RT-PCR (RT-qPCR) utilising pre-printed TaqMan
low density array (TLDA) microfluidic cards (Human miR
v2.0, Applied Biosystems) as described [47]. Each TLDA
card set contained MGB-labelled probes specific to 662
mature miRNAs plus six proposed small nuclear (sn)/
small nucleolar (sno) RNA candidate EC reference genes
(MammU6, RNU44, RNU48, RNU24, RNU43, RNU6B).
Assays for three of these candidate EC reference genes
(MammU6, RNU44 and RNU48) were included on TLDA
cards A and B, and the other three (RNU24, RNU43 and
RNU6B) were only present on TLDA card B. Details of
these candidate EC reference genes and the number of
technical replicates found on TLDA cards A and B are
provided in Table 5. Pre-processing of raw TLDA data
files consisted of threshold and baseline corrections for
each sample, with each amplification plot assessed toTable 5 Small nuclear and small nucleolar RNA candidate EC
Gene Length (nt) RNA species Entrez Gene ID Replicat
RNU48 63 snoRNA NR_002745 1
RNU44 61 snoRNA NR_002750 1
RNU43 62 snoRNA NR_002439 0
RNU24 75 snoRNA NR_002447 0
RNU6B 45 snoRNA NR_002752 0
MammU6 106 snRNA NR_004394 4
Accession numbers for each of the candidate EC reference genes and number of reconfirm that the quantification cycle (Cq) value corre-
sponded with the midpoint of logarithmic amplification
(SDS 2.3, Life Technologies, Melbourne). Cq values
greater than 32 were imputed to 32 according to the man-
ufacturer’s technical recommendation.
Statistical analysis
Statistics used for the filtering of candidate EC reference
genes from TLDA cards were calculated in R statistical
environment version 2.13.0 [65] and candidates were fil-
tered according to three criteria: (1) candidate EC refer-
ence genes must be moderately to highly expressed
across all samples, defined as a mean Cq of ≤ 25; (2) can-
didate EC reference genes must be consistently
expressed between the combined CD133+ NSCs and
CD133- NPCs, and primary MB specimens, with signifi-
cantly differentially expressed miRNAs identified using a
two sample t-test (P < 0.05) and a absolute differential
expression fold change (FC) value of 1.5 ( |FC| ≥ 1.5); (3)
candidate EC reference genes must be uniformly
expressed across all samples, with a coefficient of vari-
ation (CV) < 10. The coefficient of variation (CV) is the
ratio of the standard deviation to the mean expressed as
a percentage and is a measure of expression variability
of candidate EC reference genes across all samples. Can-
didate EC reference genes that met these criteria (see
Table 2) were deemed suitable for subsequent analysis
using the geNorm [36] and NormFinder [46] software.
The geNorm algorithm calculates the gene expression
stability measure (M) for a candidate EC reference gene
based upon the average pairwise variation (V) for that
gene against all other tested candidate EC reference
genes [36]. NormFinder, a Microsoft Excel add-in, is
based upon an analysis of variance (ANOVA) model
which estimates an intra- and inter-group variation to
provide a stability value for each candidate EC reference
gene [46]. Normfinder provides the single most stable
reference gene, in addition to an EC reference gene pair
that has a stability value less than that of the single EC
reference gene. Prior to NormFinder analyses, Cq values
were converted to relative expression values using the 2-
Cq method [66]. In both programs, lower values indicate
increased stability of EC reference genes, and thereforereference genes included on TLDA cards







plicates per card are also listed.
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of the target TLDA card B miRNAs hsa-miR-923,
hsa-miR-144* and hsa-miR-21* were further normal-
ised to each selected EC reference gene and relative
expression was determined using the 2-ΔCq method,
where ΔCq= (CqmiR – Cqendogenous control gene). To iden-
tify differential expression of individual miRNAs, the
normalised means [log2(2
-ΔCq)] of expression levels for
each miRNA in primary MB specimens were compared
to the normalised means (log2(2
-ΔCq) of expression for
that miRNA in CD133+ NSCs and CD133-NPCs. For
CD133+ NSCs and CD133- NPCs, normalised means
(log2(2
-ΔCq) of expression levels were obtained by aver-
aging the expression of individual miRNAs from both
hES3 and Mel1, therefore representing a pool of two ESC
cell lines.
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